BUZZ-Jazz Pharma jumps after cancer drug meets main goal in late-stage study
Jazz Pharmaceuticals' shares rose 13.4% premarket after its cancer drug, Ziihera, met main goals in a late-stage study for stomach cancer treatment. The study showed significant improvements in survival rates. Jazz shares rights with Zymeworks, whose shares also increased by 43.52% premarket. Jazz plans to submit a marketing application to the FDA in H1 2026. Ziihera is already approved for biliary tract cancer treatment. As of last close, Jazz shares are up 14.6% and Zymeworks 26.5% YTD.
Shares of drugmaker Jazz Pharmaceuticals (JAZZ.O) rise 13.4% to $160 premarket
Company says its drug, Ziihera, in combination with chemotherapy, met main goals in a late-stage study for the treatment of a type of stomach cancer
In the study, Ziihera showed meaningful and statistically significant improvements in progression-free and overall survival in patients compared to those on standard of care in combination with chemotherapy - JAZZ
JAZZ shares rights of the therapy with Zymeworks (ZYME.O) , shares of which are also up 43.52% premarket
Co plans to submit a marketing application to the U.S. FDA for this indication in H1 2026
Ziihera is already approved in the U.S. for the treatment of a type of biliary tract cancer
As of last close, JAZZ up 14.6% and ZYME up 26.5% YTD
